Earnings Preview: CHRS to Report Financial Results Post-market on May 12
Coherus to Report First Quarter 2025 Financial Results on May 12, 2025
Coherus to Participate in Upcoming Investor Conferences
H.C. Wainwright Maintains Coherus BioSciences(CHRS.US) With Buy Rating, Maintains Target Price $7
Express News | HC Wainwright & Co. Reiterates Buy on Coherus BioSciences, Maintains $7 Price Target
Promising Clinical Data and Strategic Expansion Justify Buy Rating for Coherus Biosciences
Coherus BioSciences Reports Promising Clinical Data for CHS-114 Combined With Toripalimab in HNSCC and Gastric Cancer
Coherus Biosciences: Data From Ongoing Phase 1 Clinical Trial Evaluating CHS-114 Shows Clinical Efficacy And Proof Of Mechanism In HNSCC In Combination With Toripalimab
Coherus Presents Promising Early Clinical Data From Phase 1 Dose Expansion Study of CHS-114 in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma at AACR 2025
Coherus BioSciences Price Target Cut to $1.05/Share From $1.50 by UBS
Coherus BioSciences Is Maintained at Neutral by UBS
Coherus BioSciences Analyst Ratings
New Analyst Forecast: $CHRS Given $1.05 Price Target
Coherus Biosciences CCO Resigns After UDENYCA Divestiture
Sector Update: Health Care
Coherus BioSciences Completes Sale of Udenyca Franchise to Intas Pharmaceuticals for Up to $558.4 Million
Express News | Accord Biopharma, Inc. Announces Completion of Udenyca® (Pegfilgrastim-Cbqv) Franchise Acquisition From Coherus BioSciences, Inc., Expanding U.S. Biosimilar Portfolio
Express News | Coherus Completes Strategic Transformation With Successful Divestiture of Udenyca® Franchise
Coherus Completes Strategic Transformation With Successful Divestiture of UDENYCA Franchise
Coherus Announces Repurchase of Approximately $170 Million of Convertible Notes